Everything below concerns angiotensin IV. We keep the language plain, cite what the science says, and separate well-supported claims from open questions.
Last reviewed on 2026-03-23. Where a claim depends on a specific study, the study is described rather than over-claimed.
Dihexa is a synthetic peptide with the chemical name N-hexanoic-Tyr-Ile-(6)-aminohexanoic amide, and it is structurally related to angiotensin IV, a naturally occurring peptide fragment. Researchers developed it as a modified analog intended to alter stability and activity relative to the parent peptide. Its short sequence and fatty acid chain distinguish it from many endogenous peptides, and published studies often describe it under the abbreviation dihexa. The compound is classified as a laboratory compound rather than an approved therapeutic in most jurisdictions.
Early laboratory work focused on its effects on synaptic connectivity and neuronal signaling. In cell and animal models, dihexa has been reported to promote the formation of new synapses, a process called synaptogenesis. These findings have generated interest in cognitive research, but the evidence base remains mostly preclinical. Human clinical trials with clear safety and efficacy endpoints are limited or absent in the public literature. Whether these effects translate to humans is an open question.
The proposed mechanism involves interaction with the hepatocyte growth factor (HGF) system and its receptor, c-Met. Dihexa is described in some studies as an HGF mimetic, meaning it may mimic or enhance HGF-mediated signaling. Activation of c-Met can influence cell growth, survival, and cytoskeletal remodeling, pathways that intersect with synaptic plasticity. However, the precise binding targets and downstream events for dihexa are not fully established, and alternative mechanisms have been suggested.
Dihexa is a synthetic peptide that has been examined in laboratory and animal research. Its design is based on angiotensin IV, a naturally occurring peptide fragment produced in the body. The short name dihexa appears in scientific papers and online discussions, while the full chemical name describes a modified peptide chain. It is not a vitamin, mineral, or plant-derived compound. Suppliers typically present it as a research chemical rather than an approved medicine.
The full name often given is N-hexanoic-Tyr-Ile-(6)-aminohexanoic amide. This name indicates a chain containing tyrosine, isoleucine, and a six-carbon amino acid derivative. Databases list a CAS Registry Number and a molecular formula for the compound. The peptide is small compared with proteins, and its structure allows it to be studied in cell cultures and animal models. Exact identity depends on the supplier's synthesis and purification process. Minor impurities can remain after synthesis.
| Property | Value | Notes |
|---|---|---|
| Chemical name | N-hexanoic-Tyr-Ile-(6)-aminohexanoic amide | Common full name in research literature. |
| Class | Synthetic peptide | Modified angiotensin IV analog. |
| Related compound | Angiotensin IV | Parent peptide fragment. |
| Proposed target | HGF/c-Met pathway | Described as an HGF mimetic; not fully confirmed. |
| Development status | Preclinical research | No widely approved clinical use. |
Dihexa is a synthetic compound studied in laboratory and animal models for effects on synaptic connectivity and cognitive performance. It is often described as a peptide analog because its structure incorporates amino acid residues linked to a hexanoic acid group. The molecule is not a naturally occurring human hormone or neurotransmitter. Its name appears in research literature and online discussions, but it has not been approved as a medicine by major regulatory agencies. Most information comes from preclinical experiments rather than controlled human trials.
The compound originated from work on angiotensin IV, a peptide fragment of the renin-angiotensin system. Researchers modified angiotensin IV-related structures to produce molecules with altered stability and activity. Dihexa emerged from that effort and was reported to promote dendritic spine growth in cultured neurons. Some studies link its effects to hepatocyte growth factor signaling and the c-Met receptor, while other work points to insulin-regulated aminopeptidase. The precise primary target remains a subject of investigation, and findings may depend on cell type, assay conditions, and species.
The compound has been examined in animal models for effects on learning, memory, and synaptic connectivity. Some reports describe increased dendritic spine density and improved performance on certain behavioral tasks after administration in rodents. These findings are often cited in discussions of nootropic research peptides, but replication across independent laboratories remains limited. The absence of published phase 1 or phase 2 clinical trial data makes it difficult to assess safety, effective routes, or long-term outcomes in humans. Consequently, claims about cognitive benefits in people remain speculative.
Dihexa is not approved as a medicine in major regulatory jurisdictions. It is commonly sold as a research chemical for laboratory use, though such products may not be standardized or independently verified. Scientific literature on dihexa includes in vitro assays, rodent studies, and reviews that discuss its proposed mechanism. The distinction between peer-reviewed findings and commercial promotion is important when evaluating available information. Open questions include its precise binding interactions, pharmacokinetics, and whether animal results translate to human biology.
Dihexa is a synthetic peptide studied in preclinical neuroscience. It is often described as an angiotensin IV analog or derivative. The compound also appears under research codes such as PNB-0408 and N-hexanoic-Tyr-Ile-(6)-aminohexanoic amide. It is not an approved drug, and it is not a conventional vitamin or nutrient. In many jurisdictions, material sold as dihexa is handled as a research chemical rather than a medicine or supplement. This classification affects how the material is labeled and distributed.
Chemically, dihexa is a short peptide-like molecule with nonstandard components. Its structure includes tyrosine and isoleucine residues linked to a hexanoic acid group and an aminohexanoic amide segment. This design distinguishes it from endogenous angiotensin IV, though the two are discussed together because of shared origins. Published summaries classify it as a small synthetic peptide with lipophilic features that may influence how it crosses biological barriers in experimental systems. Exact conformational details depend on the specific salt or free base form.
Regulatory treatment varies by country. Dihexa does not appear in major pharmacopeias as a licensed therapeutic substance. Suppliers may use labels such as research use only or not for human consumption. Such labels reflect legal and quality-control boundaries rather than evidence of clinical benefit. Importation, possession, and sale can be restricted depending on local laws, and enforcement focuses on claims, distribution channels, and product categories. These rules can change, and they differ from rules for approved medicines.
== History == Mycophenolic acid was discovered by Italian medical scientist Bartolomeo Gosio. Gosio collected a fungus from spoiled corn and named it Penicillium glaucum. (The species is now called P. brevicompactum.) In 1893 he found that the fungus had antibacterial activity. In 1896 he isolated crystals of the compound, which he successfully demonstrated as the active antibacterial compound against the anthrax bacterium. This was the first antibiotic that was isolated in pure and crystalline form. But the discovery was forgotten. It was rediscovered by two American scientists C.L. Alsberg and O.M. Black in 1912, and given the name mycophenolic acid. The compound was eventually demonstrated to have antiviral, antifungal, antibacterial, anticancer, and antipsoriasis activities. Although it is not commercialised as antibiotic due to its adverse effects, its modified compound (ester derivative) is an approved immunosuppressant drug in kidney, heart, and liver transplantations, and is marketed under the brands Cellcept (mycophenolate mofetil by Roche) and Myfortic (mycophenolate sodium by Novartis). Cellcept was developed by a South African geneticist Anthony Allison and his wife Elsie M. Eugui. In the 1970s while working at the Medical Research Council, Allison investigated the biochemical causes of immune deficiency in children. He discovered the metabolic pathway involving an enzyme, inosine monophosphate dehydrogenase, which is responsible for undesirable immune response in autoimmune diseases, as well as for immune rejection in organ transplantation.
== Biochemistry == ACC is the precursor to the plant hormone ethylene. It is synthesized by the enzyme ACC synthase (EC 4.4.1.14) from methionine and converted to ethylene by ACC oxidase (EC 1.14.17.4). ACC also exhibits ethylene-independent signaling that plays a critical role in pollination and seed production by activating proteins similar to those involved in nervous system responses in humans and animals. More specifically, ACC signaling promotes secretion of the pollen tube chemoattractant LURE1.2 in ovular sporophytic tissue thus enhancing pollen tube attraction. Additionally, ACC activates Ca2+-containing ion currents via glutamate receptor-like (GLR) channels in root protoplasts. ACC can be used by soil microorganisms (both bacteria and fungi) as a source of nitrogen and carbon. As such, using ACC to incubate soils has been proven to induce the gene abundance encoding ACC-deaminases, which may have positive consequences on plant growth and stress tolerance. ACC has also been extracted from kelp. ACC is also an exogenous partial agonist of the mammalian NMDA receptor. In 2019, the United States Environmental Protection Agency issued notice of an application for an experimental use permit to be issued for use of ACC as a pesticide.
=== Flame retardants === Compounds of boron, silicon, arsenic, and antimony have been used as flame retardants. Boron, in the form of borax, has been used as a textile flame retardant since at least the 18th century. Silicon compounds such as silicones, silanes, silsesquioxane, silica, and silicates, some of which were developed as alternatives to more toxic halogenated products, can considerably improve the flame retardancy of plastic materials. Arsenic compounds such as sodium arsenite or sodium arsenate are effective flame retardants for wood but have been less frequently used due to their toxicity. Antimony trioxide is a flame retardant. Aluminium hydroxide has been used as a wood-fibre, rubber, plastic, and textile flame retardant since the 1890s. Apart from aluminium hydroxide, use of phosphorus based flame-retardants – in the form of, for example, organophosphates – now exceeds that of any of the other main retardant types. These employ boron, antimony, or halogenated hydrocarbon compounds.
Sources: en.wikipedia.org
==== Copper ==== The antimicrobial mechanisms of copper have been studied for decades and are still under investigation. A summary of potential mechanisms is available here: Antimicrobial properties of copper#Mechanisms of antibacterial action of copper. Researchers today believe that the most important mechanisms include the following:
=== PDF generation === ColdFusion can generate PDF documents using standard HTML (i.e. no additional coding is needed to generate documents for print). CFML authors place HTML and CSS within a pair of cfdocument tags (or new in ColdFusion 11, cfhtmltopdf tags). The generated document can then either be saved to disk or sent to the client's browser. ColdFusion 8 introduced also the cfpdf tag to allow for control over PDF documents including PDF forms, and merging of PDFs. These tags however do not use Adobe's PDF engine but cfdocument uses a combination of the commercial JPedal Java PDF library and the free and open source Java library iText. The library used by cfhtmltopdf since cf11 has been an embedded WebKit IMPLEMENTATION. Since cf2023, Adobe has licensed PDFReactor to be the default engine underlying cfhtmltopdf.
Such activity requires the proteasome to cleave the substrate protein internally, rather than processively degrading it from one terminus. It has been suggested that long loops on these proteins' surfaces serve as the proteasomal substrates and enter the central cavity, while the majority of the protein remains outside. Similar effects have been observed in yeast proteins; this mechanism of selective degradation is known as regulated ubiquitin/proteasome dependent processing (RUP).
Sources: en.wikipedia.org
Susan Weintraub is an American scientist. She is a professor at the University of Texas Health Science Center at San Antonio (UTHSCSA). She received a BS in chemistry from the University of Pennsylvania in 1967, MS in chemistry from Trinity University in 1970 and a PhD in biochemistry from UTHSCSA in 1979. She was the president of the American Society for Mass Spectrometry for the period of 2012-2014. In 2017 she was named a Fellow of the American Association for the Advancement of Science (AAAS), and Fellow of the American Society for Mass Spectrometry in 2025. She is an associate editor of the Journal of Proteome Research. Her research focuses on biomedical mass spectrometry where she used mass spectrometry in the early 1970s for quantitative analysis of brain neurochemicals. She has been director of the mass spectrometry core resource at UTHSCSA since 1979.
, not all individuals of the population have been removed, so some must remain susceptible. A driving force leading to the end of an epidemic is a decline in the number of infectious individuals. The epidemic does not typically end because of a complete lack of susceptible individuals. The role of both the basic reproduction number and the initial susceptibility are extremely important. In fact, upon rewriting the equation for infectious individuals as follows:
While under TBN, the Bakkers moved to Charlotte, North Carolina, where in May 1973 they launched an east coast version of Praise The Lord under TBN's umbrella. Less than a year later the Bakkers formed their own non profit organization, registered the PTL trademark, left the umbrella of TBN and the Crouches, and continued their show on 36 WRET Charlotte, 16 WGGS Greenville, South Carolina, and a few other stations. In 1975, they nationally debuted their own late night-style talk show, known as The PTL Club. Bakker founded the PTL Satellite Network in 1974, which aired The PTL Club and other religious television programs through local affiliates across the U.S.
A 2017 study finds that countries' coup-proofing strategies are heavily influenced by other countries with similar histories. Coup-proofing is more likely in former French colonies. A 2018 study in the Journal of Peace Research found that leaders who survive coup attempts and respond by purging known and potential rivals are likely to have longer tenures as leaders. A 2019 study in Conflict Management and Peace Science found that personalist dictatorships are more likely to take coup-proofing measures than other authoritarian regimes; the authors argue that this is because "personalists are characterized by weak institutions and narrow support bases, a lack of unifying ideologies and informal links to the ruler". In their 2022 book Revolution and Dictatorship: The Violent Origins of Durable Authoritarianism, political scientists Steven Levitsky and Lucan Way found that political-military fusion, where the ruling party is highly interlinked with the military and created the administrative structures of the military from its inception, is extremely effective at preventing military coups. For example, the People's Liberation Army was created by the Chinese Communist Party during the Chinese Civil War, and never instigated a military coup even after large-scale policy failures (i.e. the Great Leap Forward) or the extreme political instability of the Cultural Revolution. Some scholars have posited that the recruitment of foreign legionnaires into national armies can reduce the probability of military coups.
Sources: en.wikipedia.org
Dihexa is a synthetic peptide analog of angiotensin IV, often described as an HGF mimetic in research literature. It is studied for effects on synaptic connectivity in laboratory models. It is not an approved medication.
No, dihexa is a synthetic compound derived from the structure of angiotensin IV. Angiotensin IV occurs naturally, but dihexa has modifications that change its properties. It is not a standard dietary component.
The main hypothesis is that dihexa interacts with the hepatocyte growth factor system, possibly through c-Met signaling. This interaction may influence synaptogenesis and neuronal plasticity. The exact molecular target remains an active area of study.
Dihexa is a synthetic peptide modeled on angiotensin IV. It is used in laboratory and animal research, not as an approved medicine. Human effects remain poorly characterized.